Mingming Zhang

Mingming Zhang

Auto-generated profile, based on publicly available information

Mingming Zhang

Affiliations Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada, UBC Centre for Heart Lung Innovation, St. Paul’s Hospital, Vancouver, British Columbia, Canada, Providence Research, Providence Health Care, Vancouver, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Ceramics International
Verified
Journal Article
Closed access
MZMingming Zhang
Mingming Zhang
YNYunsong Niu
Yunsong Niu
LXLi Xin
Li Xin
JSJianxiu Su
Jianxiu Su
YLYongfeng Li
Yongfeng Li
FWFuhui Wang
Fuhui Wang

1 June 2023 in Journal of Breath Research
Verified
Journal Article
Open access
NSNing Sun
Ning Sun
PKPreethi Krishnan
Preethi Krishnan
CRChristiaan A Rees
Christiaan A Rees
MZMingming Zhang
Mingming Zhang
KSKeisean A J M Stevenson
Keisean A J M Stevenson
Jane Emily HillJane Emily Hill
Jane Emily Hill
Volatile organic compounds (VOCs) originating from human metabolic activities can be detected in, for example, breath, urine, feces, and blood. Thus, attention has been given to identifying VOCs from the above matrices. Studies identifying and measuring human blood VOCs are limited to those focusing on monitoring specific pollutants, or blood storage and/or decomposition. However, a comprehensive characterization of VOCs in human blood collected for routine diagnostic testing is lacking. In this pilot study, 72 blood-derived plasma samples were obtained from apparently healthy adult participants. VOCs were extracted from plasma using solid-phase microextraction and analyzed using comprehensive two-dimensional gas chromatography tandem time-of-flight mass spectrometry. Chromatographic data were aligned, and putative compound identities were assigned via spectral library comparison. All statistical analysis, including contaminant removal, data normalization, and transformation were performed using R. We identified 401 features which we called the pan volatilome of human plasma. Of the 401 features, 34 were present in all the samples with less than 15% variance (core molecules), 210 were present in ⩾10% but <100% of the samples (accessory molecules), and 157 were present in less than 10% of the samples (rare molecules). The core molecules, consisting of aliphatic, aromatic, and carbonyl compounds were validated using 25 additional samples. The validation accuracy was 99.9%. Of the 34 core molecules, 2 molecules (octan-2-one and 4-methyl heptane) have been identified from the plasma samples for the first time. Overall, our pilot study establishes the methodology of profiling VOCs in human plasma and will serve as a resource for blood-derived VOCs that can complement future biomarker studies using different matrices with more heterogeneous cohorts.

3 April 2026 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
MZMingming Zhang
Mingming Zhang
YKYoung Woong Kim
Young Woong Kim
CYChen Xi Yang
Chen Xi Yang
GGGail M. Gauvreau
Gail M. Gauvreau
JFJohn Marcus FitzGerald
John Marcus FitzGerald
ASAmrit Singh
Amrit Singh
Background: The allergen-induced late-phase asthmatic response (LAR) is used to study the mechanisms and treatment of asthma. We hypothesized that gene-expression (mRNA) biomarkers of the LAR may predict asthma exacerbations and severity. Methods: Individuals with mild allergic asthma underwent inhaled allergen challenge. We identified a baseline blood-based mRNA biomarker panel predictive of LAR development and combined it with previously reported LAR-associated biomarkers. These LAR-mRNA biomarkers were evaluated in multiple public gene-expression datasets spanning blood, airways, bronchoalveolar lavage fluid (BALF), and induced sputum to assess their ability to discriminate asthma exacerbations and severity. Cellular specificity and allergen responsiveness were examined using public single-cell RNA sequencing datasets from endobronchial biopsies obtained before and after segmental allergen challenge. To identify potential therapeutics, we performed drug-signature matching using a public single-cell perturbation dataset to identify compounds capable of reversing LAR-associated, cell-specific transcriptional changes. Results: A combined set of 109 LAR-mRNA biomarkers was identified and shown to predict asthma exacerbations, with stronger performance in males than females. Biomarker-based prediction of asthma severity was most robust in BALF and induced sputum compared with blood. Highly predictive transcripts included the RNA-binding proteins GNAS and SF3B1 across multiple sample types. Single-cell analyses revealed that allergen challenge selectively altered the expression of LAR-mRNA biomarkers in T cell populations, including CD8 T cells ( CLIC3 + and GZMK +), CD4 Th17 ( RORA +) cells, CD4 ( CD40LG +) T cells, and γδ ( TRDC +) T cells, with minimal changes in allergic controls. Drug-signature matching identified corticosteroids such as mometasone furoate and prednisolone, as well as the heat shock protein 90 inhibitor AT13387, as compounds predicted to reverse these cell-specific transcriptional signatures. Conclusion: LAR-mRNA biomarkers reflect an asthma-specific inflammatory state that predisposes individuals to late-phase responses, exacerbations, and progression to more severe disease. These findings link systemic biomarkers to airway cellular mechanisms and nominate therapeutic strategies to modulate allergen-driven inflammation.